Filing Details

Accession Number:
0001209191-14-075984
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-12-16 18:36:53
Reporting Period:
2014-12-12
Filing Date:
2014-12-16
Accepted Time:
2014-12-16 18:36:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
861838 Idera Pharmaceuticals Inc. IDRA Biological Products, (No Disgnostic Substances) (2836) 043072298
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1193366 El Youssef Zein C/O Idera Pharmaceuticals, Inc.
167 Sidney Street
Cambridge MA 02139
Yes No Yes No
1534425 Pillar Pharmaceuticals I Lp Pillar Invest Offshore Sal, Starco Ctr,
Bloc B, 3Rd Floor, Omar Daouk Street
Beirut M8 2020-3313
Yes No Yes No
1534428 Pillar Invest Corp C/O Idera Pharmaceuticals, Inc.
167 Sidney Street
Cambridge MA 02139
Yes No Yes No
1562069 Pillar Pharmaceuticals Ii, L.p. Pillar Invest Offshore Sal, Starco Ctr
Bloc B, 3Rd Floor, Omar Daouk Street
Beirut M8 2020-3313
Yes No Yes No
1576891 Pillar Pharmaceuticals Iii, L.p. Pillar Invest Offshore Sal Starco Ctr
Bloc B, 3Rd Floor Omar Daouk Street
Beirut M8 2020-3313
Yes No Yes No
1588130 Pillar Pharmaceuticals Iv, L.p. Pillar Invest Offshore Sal Starco Ctr
Bloc B, 3Rd Floor, Omar Daouk Street
Beirut M8 2020-3313
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-12-12 160,521 $0.00 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2014-12-12 44,143 $0.00 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2014-12-12 32,104 $0.00 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2014-12-12 24,078 $0.00 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2014-12-15 178,462 $0.00 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2014-12-15 49,077 $0.00 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2014-12-15 35,692 $0.00 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2014-12-15 26,769 $0.00 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2014-12-16 339,018 $0.00 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2014-12-16 93,230 $0.00 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2014-12-16 67,804 $0.00 0 No 4 S Indirect See Footnotes
Common Stock Disposition 2014-12-16 50,853 $0.00 0 No 4 S Indirect See Footnotes
Common Stock Acquisiton 2014-12-11 2,218,020 $0.00 0 No 4 C Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 C Indirect See Footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series E Convertible Preferred Stock Disposition 2014-12-16 110,901 $0.00 2,218,020 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
Footnotes
  1. Shares sold by Pillar Pharmaceuticals I, L.P. ("Pillar I"), of which Pillar Invest Corporation ("Pillar GP") is the general partner. Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar I and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar I. As of the date hereof, Pillar I owns directly 2,969,838 shares of common stock of the Issuer.
  2. Shares sold by Pillar Pharmaceuticals II, L.P. ("Pillar II"), of which Pillar GP is the general partner. Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar II and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar II. As of the date hereof, Pillar II owns directly 6,782,085 shares of common stock of the Issuer.
  3. Shares sold by Pillar Pharmaceuticals III, L.P. ("Pillar III"), of which Pillar GP is the general partner. Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar III and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar III. As of the date hereof, Pillar III owns directly 2,219,581 shares of common stock of the Issuer.
  4. Shares sold by Pillar Pharmaceuticals IV, L.P. ("Pillar IV"), of which Pillar GP is the general partner. Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar IV and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar IV. As of the date hereof, Pillar IV owns directly 559,847 shares of common stock of the Issuer.
  5. Youssef El Zein is a director and controlling stockholder of Pillar GP and serves as the representative of a Pillar I, Pillar II, Pillar III, Pillar IV and Pillar GP on the Issuer's board of directors. Mr. El Zein disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar I, Pillar II, Pillar III, Pillar IV and Besancon and this report shall not be deemed an admission that he is the beneficial owners of any such securities, except to the extent of his pecuniary interest therein, if any, by virtue of his ownership interest in Pillar GP. As of the date hereof, Mr. El Zein owns directly 486,101 shares of common stock of the Issuer.
  6. Shares of Common Stock are held directly by Participations Besancon ("Besancon"), a fund advised by Pillar GP. Pillar GP disclaims Section 16 beneficial ownership of the Besancon Common Stock and this report shall not be deemed an admission that Pillar GP is the beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, resulting from fees payable to Pillar GP in its capacity as investment advisor to Besancon. As of the date hereof, Besancon owns directly 5,657,953 shares of common stock of the Issuer.
  7. On December 16, 2014, Besancon converted 110,901 shares of Series E Convertible Preferred Stock, on a 1-for-20 basis, into 2,218,020 shares of Common Stock.